Clinicopathological data of non-BRAF MAPK alterations
| ID | Path Dx (grade) | MAPK gene (alteration) | Site | Adjuvant therapy | Follow-up (months) | Relapse (#) | Relapse interval (months) | Outcome |
| 33 | Infant-type hemispheric glioma (high) | NTRK2 (KANK1::NTRK2) | Hemisphere temporal | Combination chemo | 22.3 | 1 | 21.3 | PD |
| 34 | Infant-type hemispheric glioma (low) | ROS1 (GOPC::ROS1) | Hemisphere temporal | None | 21.3 | None | None | Alive NOS |
| 35 | Angiocentric glioma (low) | MYB (MYB::QKI) | Hemisphere frontal | NA | NA | NA | NA | NA |
| 36 | DLGG, MAPK (low) | FGFR1 (FGFR1::TACC1) | Hemisphere parietal | None | 5.0 | None | None | NED |
| 37 | LGG features of PA, H3 K27M (low)* | FGFR1 (N577K) NF1 (Y1680fs) | Brain stem-4th ventricle | RT, bevacizumab | 32.4 | 2 | 12, 22.3 | PD |
| 38 | PXA (high) | NF1 (G629R) | Hemisphere frontal | RT, temozolamide | 6.1 | 1 | 5.1 | LFU |
| 39 | GBM (high) | NTRK2 (BCR::NTRK2) | Hemisphere temporal | RT, temozolamide | 53.0 | 1 | 48.8 | LFU |
| 40 | GBM (high) | FGFR1 (D162A) | Hemisphere parietal | RT, temozolamide | 11.1 | None | None | LFU |
*Not defined in the 2021 WHO book.
Alive NOS, alive not otherwise specified; DLGG, MAPK, diffuse low-grade glioma MAPK pathway-altered; GBM, glioblastoma; LFU, lost to follow‐up; NA, not available; NED, no evidence of disease; PD, progressive disease; PXA, pleomorphic xanthoastrocytoma.